Regeneron

Showing 15 posts of 105 posts found.

peanuts

Peanut allergies? There’s a clinical trial looking to fix that

October 17, 2017
Manufacturing and Production, Research and Development Aimmune, Regeneron, Sanofi, biotech, drugs, peanuts, pharma, pharmaceutical

Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …

sanofi_regeneron

Sanofi and Regeneron’s projected blockbuster gains EU approval

September 28, 2017
Sales and Marketing Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron have big hopes for their treatment Dupixent, and it has taken an important step towards reaching the …

sanofi_regeneron

Sanofi/Regeneron new asthma data bolstered by potential indications

September 13, 2017
Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …

regeneron

Regeneron abandons respiratory syncytial virus therapy after late-stage failure

August 15, 2017
Manufacturing and Production, Research and Development RSV, Regeneron, pharma, pharmaceuticals, respiratory syncytial virus

Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the …

sanofi_regeneron

New potential blockbuster RA treatment enters European market

June 27, 2017
Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi

The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …

Novartis receives positive news in eye drug P3 studies

June 20, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron

Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it …

Sanofi and Regeneron posts positive Praluent cholesterol data

June 12, 2017
Research and Development, Sales and Marketing Regeneron, Sanofi, praluent

Sanofi and Regeneron were able to update its PCSK9 therapy Praluent with the positive data showing it could reduce levels …

FDA approves first-ever atopic dermatitis biologic treatment

March 31, 2017
Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic

Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …

sanofi_regeneron

Breakthrough eczema drug given FDA approval

March 29, 2017
Research and Development, Sales and Marketing Dupixent, Regeneron, Sanofi

Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first …

shutterstock_146497481

GSK and Regeneron partner with Biobank to analyse 500,000 genetic profiles

March 23, 2017
Research and Development Biobank, GSK, Regeneron

GlaxoSmithKline and Regeneron Pharmaceuticals are to band together in a joint effort with UK Biobank – “the world’s most detailed …

Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent

February 9, 2017
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent

Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …

Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection

February 1, 2017
Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab

Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …

regeneron

Regeneron agrees ownership of HQ for $720m after 25 years

January 25, 2017
Manufacturing and Production, Medical Communications Regeneron

After leasing the property for 25 years, Regeneron has agreed to take ownership of its headquarters and buy the Landmark …

amgen_hq

Amgen’s patent win upheld against Sanofi-Regeneron

January 4, 2017
Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent

In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was …

FDA rejects Sarilumab due to production facility issues

October 31, 2016
Manufacturing and Production, Sales and Marketing FDA, Regeneron, Sanofi, sarilumab

The US Food and Drugs administration has decided to reject the application for Sarilumab, Regeneron and Sanofi’s rheumatoid arthritis treatment, …

The Gateway to Local Adoption Series

Latest content